American Express Company (AXP), Rockwell Collins Inc. (COL) & More: Here’s Why These Stocks Are Trending Today

Page 2 of 2

Juno Therapeutics Inc. (NASDAQ:JUNO) stock soared on the news of its competitor Kite Pharma receiving better than expected results from Phase II study of Kite’s KTE-C19, which showed 47% complete remission (CR) for patients with diffuse large B-cell lymphoma. Juno is also active in large B-cell lymphoma market. Its CAR-T technology is among 3-4 biotech firms developing this cutting edge area of medicine. At the end of June, 11 funds we track held about $38.9 million worth of Juno Therapeutics stock in aggregate, compared to 14 funds holding stock worth $32 million a quarter earlier.

Follow Juno Therapeutics Inc. (NASDAQ:JUNO)

Novo Nordisk A/S (ADR) (NYSE:NVO) has announced that it had initiated a share repurchase program on August 5. The buyback is part of the broader, DKK 14 billion ($2.1 billion), share repurchase program to be executed for a 12-month period starting February 2016. It involves the repurchase of DKK 3.4 billion ($500 million) worth of stock and overs the period between August 5 to October 26. The number of funds from our database long Novo Nordisk remained unchanged at 12 during the second quarter, while the total value of their holdings amounted to $1.4 billion at the end of June.

Follow Novo Nordisk A S (NYSE:NVO)

Disclosure: none

Page 2 of 2